Lymphoma News Poster Sessions

Abstract 7516 Poster Discussion Session; Displayed in Poster Session (Board #153),

Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL. First Author: David Andorsky, Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO

Conclusions: R2 therapy showed favorable activity and tolerable safety profiles in patients who had R/R FL and MZL, regardless of the number of prior anti-lymphoma therapies. Enrollment in MAGNIFY is ongoing. Clinical trial information: NCT01996865

See Abstract

 

Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST). First Author: Grzegorz S. Nowakowski, Mayo Clinic, Rochester, MN

Abstract 7548

 

Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process. First Author: Peihua Lu, Hebei Yanda Lu Daopei Hospital, Langfang, China

Abstract 3041